ACADIA Pharmaceuticals ACAD Stock Price is ready to bounce? Exclusive Report
ACADIA Pharmaceuticals ACAD Stock Price has been trying to recover since it’s July high of almost $25.33.
Wondering why this stock is having such a hard time and if it can break the overall trend? Before we do, remember to stop what you are doing and 👇 Sign up for our newsletter to get the latest breakout stocks and trending stocks!
[thrive_leads id=’14274′]
Before we get started, I wanted to introduce myself to you. Hi 🙋♂️ I’m Alexander Goldman and I have been successfully trading breakout stocks and trending stocks for two decades now.
I’m now helping traders find breakout stocks. My claim to fame is the expert at finding trending stocks.
What do I mean by big winners?
Stocks that move more than 100% in a month! ACAD Stock Price could?
Does that always happen, NO! But, I’m very good! Take a look at this article I wrote, where I called 5 stocks, 3 losers and 2 winners and they all did what I thought!
The article is HERE where I shine a spotlight on trending stocks and breakout stocks!
Now, let’s go over some of the basic information on this stock before we get in the technical analysis
ACADIA Pharmaceuticals Company Information
Company Name: ACADIA Pharmaceuticals Inc.
Ticker: ACAD
Exchange: NASDAQ
Website: https://acadia.com/
ACADIA Pharmaceuticals Company Summary:
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm’s products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
ACAD stock price is due to News?
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the outcome of the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) meeting for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The PDAC voted 9 to 3 that the evidence presented does not support a conclusion that pimavanserin is effective for the treatment of hallucinations and delusions in the ADP population.
ACAD 5 Day Chart
ACAD Stock Price Technical Analysis:
It is in consolidation mode right now and it is a wait and see game!
I really like if it can beat $14 because, like often, the sell off was emotional and there will be a bounce.
Wait for the indicators to pop off though.
[thrive_leads id=’14274′]